Integrin alpha D beta 2

Integrin alpha D beta 2

Integrin alpha D beta 2 詳細

Molecule Name
Integrin alpha-4
分子の別称
Integrin alpha D beta 2,ITGAD & ITGB2
Drug Development Progress
治験薬の数3
市販薬剤の数0
研究&開発段階Phase 2 Clinical
ターゲットの別称
CD49D,Integrin alpha-IV,ITGA4,Integrin Subunit Alpha 4,Alpha 4 Subunit Of VLA-4 Receptor,VLA-4 Subunit Alpha,Integrin, Alpha 4 (Antigen CD49D, Alpha 4 Subunit Of VLA-4 Receptor),CD49 antigen-like family member D,Very Late Activation Protein 4 Receptor, Alpha 4 Subunit,Antigen CD49D, Alpha-4 Subunit Of VLA-4 Receptor,Integrin Alpha-4,269C Wild Type,CD49d Antigen,Antigen CD49D,IA4,Integrin alpha4
バックグランド
Integrin alpha-D/beta-2 is a receptor for ICAM3 and VCAM1. May play a role in the atherosclerotic process such as clearing lipoproteins from plaques and in phagocytosis of blood-borne pathogens, particulate matter, and senescent erythrocytes from the blood. Contributes to natural killer cell cytotoxicity. Involved in leukocyte adhesion and transmigration of leukocytes including T-cells and neutrophils. Triggers neutrophil transmigration during lung injury through PTK2B/PYK2-mediated activation (PubMed:18587400). Alpha D beta 2, selectively binds ICAM-3 and does not appear to bind ICAM-1. In addition, a soluble form of alpha D beta 2 binds VCAM-1 with greater efficiency relative to ICAM-3. The I domain of alpha D contains a binding site for VCAM-1 since recombinant alpha D I domain binds specifically to VCAM-1.

Integrin alpha D beta 2 製品リスト

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
AvicursenTV-1102; ATL/TV-1102; ATL-1102; ISIS-107248Phase 2 ClinicalIonis Pharmaceuticals Inc
Multiple Sclerosis; Muscular Dystrophy, Duchenne
詳細
BIIB-107 (Biogen)BIIB-107Phase 1 ClinicalBiogen Inc
Multiple Sclerosis
詳細
ELND-004ELND-004Phase 1 ClinicalPerrigo Company Plc
Autoimmune Diseases
詳細